Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Clinical trial NCT03740165 · COMPLETED
Trial details
- NCT number
- NCT03740165
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-18
- Primary completion
- 2024-08-26
- Enrollment
- 1367
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.